Herceptin
trastuzumab · HER2/neu Receptor Antagonist
Indications & Uses
Adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer, metastatic HER2-overexpressing breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Contraindications
None with approved oncology indications. Caution in patients with pre-existing cardiac dysfunction or prior anthracycline exposure.
Side Effects & Warnings
Cardiomyopathy (decreased LVEF), infusion-related reactions, embryo-fetal toxicity, pulmonary toxicity, fever, chills, nausea, headache, and weakness.
Drug & Dietary Interactions
Administration in combination with anthracyclines substantially increases risk of severe cardiac failure.
Regulatory & Prescribing Information
FDA Approved Biologic (BLA 103792). Black Box Warning for Cardiomyopathy, Infusion Reactions, and Embryo-Fetal Toxicity.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.